NICE recommends SIRT therapy for advanced liver cancer
Hundreds of people with advanced liver cancer are set to benefit after NICE has published final draft guidance recommending a cancer treatment called selective internal radiation selective internal radiation therapy (SIRT).
SIRT is a way of giving radiation treatment for cancer via tiny radioactive beads (called microspheres) that are injected into the artery supplying blood to the tumour via a catheter from the femoral artery. This helps to minimise the risk of radiation damage to healthy surrounding tissues.
The draft guidance recommends the use of SIR-Spheres (made by SIRTEX) and TheraSphere (made by Boston Scientific) for treating advanced liver cancer that can’t be surgically removed and when a procedure to cut off the blood supply to the tumour isn’t appropriate.
Although the clinical trial data for these SIRTs compared with other treatment options are limited, the committee concluded that, compared with systemic therapy sorafenib, they may have fewer and more manageable side-effects, which can improve quality of life.
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Assessment at NICE, said: “Unlike current systemic therapy for advanced liver cancer, which is given over a long time period and can have persistent side effects, SIRT is a locally targeted one-off treatment option.
“This draft guidance will provide people with advanced liver cancer the opportunity to benefit from an effective treatment which, importantly in terms of quality of life, is likely to have fewer and less severe side effects than standard systemic therapy.”
Pamela Healy OBE, chief executive of the British Liver Trust, said: “The British Liver Trust is delighted that NICE has now approved the use of SIRT as an option for treating unresectable advanced hepatocellular carcinoma in adults. Hepatocellular carcinoma is the most common form of liver cancer. It is particularly aggressive and a diagnosis is devastating for patients and carers. Treatment options for patients with advanced liver cancer have been very limited and this decision will make this innovative treatment more easily available and improve options for patients. Evidence shows that outcomes for people with advanced liver cancer are particularly poor so this is a really important step.”
Hepatocellular carcinoma is a cancer that starts in the liver, not as the result of tumours spreading to the liver from other parts of the body. It is the most common form of liver cancer in England, accounting for 55% of primary liver cancer diagnoses in men and 28% of diagnoses in women. There were 4,975 people diagnosed with HCC in England in 2017 of whom around 1,780 would be eligible for treatment with SIRT.